Cargando…

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis

BACKGROUND: The purpose of the present meta-analysis was to compare the efficacy of rifaximin and nonabsorbable disaccharides (NADs) in hepatic encephalopathy (HE). METHODS: After the registration of the present meta-analysis on INPLASY, all procedures were performed according to PRISMA 2020. Releva...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Junxiong, Chen, Yafang, Cao, Wenfu, Zuo, Guoqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701975/ https://www.ncbi.nlm.nih.gov/pubmed/34941089 http://dx.doi.org/10.1097/MD.0000000000028232

Ejemplares similares

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

What Improves Minimal Hepatic Encephalopathy: Probiotic Yogurt, Protein Restriction or Nonabsorbable Disaccharides?
por: Alfawaz, Hanan A., et al.
Publicado: (2012)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Probiotics and rifaximin for the prevention of travelers’ diarrhea: A systematic review and network meta-analysis
por: Fan, Hao, et al.
Publicado: (2022)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis
por: Bian, Jin, et al.
Publicado: (2017)

Primary prevention of hepatic encephalopathy post-TIPS: A systematic review and meta-analysis
por: Liang, Aileen, et al.
Publicado: (2023)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Effect of eradicating hydrogen-forming small intestinal bacterial overgrowth with rifaximin on body weight change
por: Lee, Seok-Hoon, et al.
Publicado: (2019)

Retention enema with traditional Chinese medicine for hepatic encephalopathy: A protocol for a systematic review and meta-analysis
por: Liang, Xiao, et al.
Publicado: (2020)

Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
por: Tocia, Cristina, et al.
Publicado: (2021)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Integrated analysis of differentially expressed genes, differentially methylated genes, and natural compounds in hepatitis C virus-induced cirrhosis
por: Cheng, Junxiong, et al.
Publicado: (2022)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Application of fecal microbial transplantation in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
por: Li, Jun, et al.
Publicado: (2022)

A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy
por: Vadhariya, Aisha, et al.
Publicado: (2020)

Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis
por: Fu, Jian, et al.
Publicado: (2022)

CLIF–SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis
por: Jeong, Jin Hee, et al.
Publicado: (2016)

General anesthesia in patients with hepatic encephalopathy and acute variceal bleeding undergoing endoscopic treatment: A retrospective study
por: Chen, Tao, et al.
Publicado: (2023)

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan
por: Sakamaki, Akira, et al.
Publicado: (2021)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study
por: Wang, Chun-Hsiang, et al.
Publicado: (2020)

Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides
por: Morgan, Marsha Y.
Publicado: (2016)

Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis
por: Elmoursi, Ahmed, et al.
Publicado: (2023)

Transmission of Hepatitis B and C Virus Infection Through Body Piercing: A Systematic Review and Meta-Analysis
por: Yang, Shigui, et al.
Publicado: (2015)

Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis
por: Zhang, Tianyao, et al.
Publicado: (2019)

Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy
por: Fujiwara, Yudai, et al.
Publicado: (2021)

Laparoscopic versus open surgery in the treatment of hepatic hemangioma: A meta-analysis
por: Jien, He, et al.
Publicado: (2021)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h1g4989nut611dmq6msffmaf29